首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Blood and lymphatic cancer-targets and therapy

缩写:

ISSN:1179-9889

e-ISSN:1179-9889

IF/分区:4.9/Q1

文章目录 更多期刊信息

共收录本刊相关文章索引85
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Yun-Li Xie,Long-Feng Ke,Wen-Wen Zhang et al. Yun-Li Xie et al.
Introduction: The tumor microenvironment (TME) influences diffuse large B-cell lymphoma (DLBCL) progression, but the prognostic roles of tumor-infiltrating T-lymphocytes (TIL-T), tumor-associated macrophages (TAMs), and P...
Mohammed Mohammed Battah,Hadzliana Zainal,Doa&#x;a Anwar Ibrahim et al. Mohammed Mohammed Battah et al.
Background: Drug-related problems (DRPs) are critical challenges in oncology practice, particularly among patients with non-Hodgkin lymphoma (NHL), due to complex regimens and high toxicity potential. ...
Mengyuan Gu,Yanting Zheng,Yifan Wang et al. Mengyuan Gu et al.
Purpose: The study was constructed for investigating the serum expression levels of ATIC with multiple myeloma (MM) patients and its potential clinical value as a biomarker, and analyzing its association with disease stag...
Di Zhang,Yongjian Li,Tingting Liu et al. Di Zhang et al.
Introduction: Acute myeloid leukemia (AML) prognosis remains challenging due to limited biomarkers integrating tumor microenvironment (TME) dynamics. Neutrophils, key mediators of immune regulation, exhibit dual roles in ...
Liangquan Geng,Erling Chen,Yanping Ji et al. Liangquan Geng et al.
Introduction: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for higher-risk myelodysplastic syndromes (MDS), but optimal timing and donor selection remain controversial. ...
Mengyao Zhang,Runyu Yang,Yue Du et al. Mengyao Zhang et al.
Background: Primary central nervous system lymphoma (PCNSL) is a highly aggressive extranodal non-Hodgkin's lymphoma. Moreover, there is currently no specific prognostic model for elderly PCNSL patients. ...
Amer M Zeidan,Eunice Wang Amer M Zeidan
Acute myeloid leukemia (AML) is a heterogeneous malignancy characterized by diverse genetic mutations, including IDH1 and IDH2, which are present in approximately 15-20% of cases. Recent clinical practice guidelines, including the 2025 NCCN...
Amer M Zeidan,Courtney DiNardo Amer M Zeidan
This podcast episode reviews recent advances in the treatment of IDH1-mutant acute myeloid leukemia (AML), focusing on the mechanisms, efficacy, and safety profiles of approved IDH1 inhibitors. The purpose is to present expert insights and ...
Emmanuel Ifeanyi Obeagu Emmanuel Ifeanyi Obeagu
Leukemia remains a major health challenge in Africa, where limited access to advanced diagnostic technologies often leads to delayed diagnosis and suboptimal treatment outcomes. This review explores the role of WHO-supported laboratory inno...
Amer M Zeidan,Sanam Loghavi Amer M Zeidan
In the first episode of the AML Expert Series, titled Unveiling the Mysteries of Molecular Testing in AML: A Guide for Oncologists, experts from Yale Cancer Center and MD Anderson Cancer Center describe the evolving landscape of molecular d...